Efficacy of penile low-intensity shockwave treatment for erectile dysfunction: correlation with the severity of cavernous artery disease.


Journal

Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132

Informations de publication

Date de publication:
Historique:
pubmed: 24 3 2021
medline: 15 12 2021
entrez: 23 3 2021
Statut: ppublish

Résumé

We analyzed the efficacy of penile low-intensity extracorporeal shockwave treatment for erectile dysfunction (ED) combined with cavernous artery disease (CAD). ED was evaluated by the International Index of Erectile Function, subdividing patients into mild and moderate/severe forms. CAD was assessed using penile color Doppler ultrasonography. Patients (n = 111) with a positive outcome after treatment, based upon the minimal clinically important difference of the International Index of ED, were followed up for 3 months and 6 months. We found a significant mean increase in the index of erectile function, with an overall improvement in hemodynamic parameters of the cavernous artery. In particular, 93.9% of the patients with mild ED without CAD responded to treatment and 72.7% resumed normal erectile function. Only 31.2% of the patients with moderate/severe ED and CAD responded to treatment, and none resumed normal erectile function. All patients with mild ED and no CAD maintained the effects of therapy after 3 months, while no patients with moderate/severe ED and CAD maintained the benefits of treatment after 3 months. Thus, patients with mild ED and no CAD have better and longer lasting responses to such treatment, with a higher probability of resuming normal erectile function than patients with moderate/severe ED and CAD.

Identifiants

pubmed: 33753581
pii: 311396
doi: 10.4103/aja.aja_15_21
pmc: PMC8451489
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-467

Déclaration de conflit d'intérêts

None

Références

PLoS One. 2014 Aug 05;9(8):e103982
pubmed: 25093816
J Sex Med. 2017 Jan;14(1):27-35
pubmed: 27986492
Inflammation. 2014 Feb;37(1):65-70
pubmed: 23948864
Int J Impot Res. 2019 May;31(3):162-169
pubmed: 30120384
Int J Urol. 2014 Oct;21(10):1041-5
pubmed: 24942563
J Urol. 2016 Sep;196(3):950-6
pubmed: 27038770
J Am Heart Assoc. 2015 Oct 27;4(10):e002440
pubmed: 26508745
Am J Physiol Cell Physiol. 2016 Sep 1;311(3):C378-85
pubmed: 27413171
J Thorac Cardiovasc Surg. 2013 Oct;146(4):971-8
pubmed: 23395097
J Sex Med. 2019 Oct;16(10):1490-1505
pubmed: 31447380
Neurourol Urodyn. 2018 Feb;37(2):699-707
pubmed: 28763567
Eur Urol. 2010 Aug;58(2):243-8
pubmed: 20451317
N Engl J Med. 2000 Jun 15;342(24):1802-13
pubmed: 10853004
Sex Med. 2019 Dec;7(4):441-450
pubmed: 31551177
Eur Urol. 2010 May;57(5):804-14
pubmed: 20189712
N Engl J Med. 2005 Sep 8;353(10):999-1007
pubmed: 16148285
J Sex Med. 2013 Mar;10(3):738-46
pubmed: 23253086
World J Mens Health. 2021 Jan;39(1):1-8
pubmed: 32648375
Circulation. 2006 Dec 19;114(25):2823-30
pubmed: 17145991
Eur Urol. 2017 Feb;71(2):223-233
pubmed: 27321373
Nat Rev Urol. 2017 Oct;14(10):593-606
pubmed: 28741629
J Sex Med. 2009 Apr;6(4):1117-1126
pubmed: 19067788
Int J Cardiol. 2013 Oct 9;168(4):4168-77
pubmed: 23915523
Int J Impot Res. 2019 May;31(3):170-176
pubmed: 30670837
Am J Cardiol. 2005 Dec 26;96(12B):19M-23M
pubmed: 16387561
Urology. 1999 Aug;54(2):346-51
pubmed: 10443736
J Biol Chem. 2014 Sep 26;289(39):27090-27104
pubmed: 25118288
Int J Impot Res. 2005 May-Jun;17(3):288-90
pubmed: 15729373
J Urol. 2000 Feb;163(2):460-3
pubmed: 10647654
Prev Med. 2000 Apr;30(4):328-38
pubmed: 10731462
Eur Urol. 2011 Nov;60(5):1010-6
pubmed: 21855209
Int J Urol. 2017 Aug;24(8):573-581
pubmed: 28697536
J Sex Med. 2019 Jan;16(1):17-26
pubmed: 30509508
Asian J Androl. 2017 Jan-Feb;19(1):26-33
pubmed: 27427555
J Sex Med. 2017 Apr;14(4):493-501
pubmed: 28258952
Urology. 1997 Jun;49(6):822-30
pubmed: 9187685
J Sex Med. 2010 Nov;7(11):3572-88
pubmed: 21040491
J Tissue Eng Regen Med. 2018 Jan;12(1):e486-e494
pubmed: 27689683
Int J Impot Res. 2000 Dec;12(6):305-11
pubmed: 11416833

Auteurs

Nicola Caretta (N)

Department of Medicine, University of Padova, Padova 35128, Italy.

Maurizio De Rocco Ponce (M)

Department of Medicine, University of Padova, Padova 35128, Italy.

Nadia Minicuci (N)

CNR, Neuroscience Institute, Padova 35128, Italy.

Ilaria De Santis (I)

Foresta Foundation Onlus for Biomedical Research, Padova 35128, Italy.

Pierfrancesco Palego (P)

Department of Medicine, University of Padova, Padova 35128, Italy.

Andrea Garolla (A)

Department of Medicine, University of Padova, Padova 35128, Italy.

Carlo Foresta (C)

Department of Medicine, University of Padova, Padova 35128, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH